Comparative Pharmacology
Head-to-head clinical analysis: D H E 45 versus TOSYMRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: D H E 45 versus TOSYMRA.
D.H.E. 45 vs TOSYMRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dihydroergotamine (DHE) is a semi-synthetic ergot alkaloid that acts as an agonist at serotonin (5-HT1B/1D) receptors, causing vasoconstriction of intracranial blood vessels and inhibition of trigeminal nerve transmission, thereby aborting migraine attacks. It also has high affinity for alpha-adrenergic receptors and moderate affinity for dopamine D2 receptors.
Sumatriptan is a selective agonist of serotonin (5-HT1B/1D) receptors, leading to vasoconstriction of intracranial blood vessels and inhibition of trigeminal nerve transmission.
1 mg intramuscularly or subcutaneously at first sign of headache, repeat hourly up to 3 mg per day, maximum 6 mg per week.
10 mg intranasally as a single dose, may repeat once after 24 hours if needed. Maximum 2 doses in 7 days.
None Documented
None Documented
2.5 hours (range 2-3.5 hours) for ergotamine; clinical context: short half-life supports its use in acute migraine, but frequent dosing risks ergotism.
Terminal elimination half-life approximately 2.5 hours; clinically relevant for dosing every 4-6 hours.
Primarily hepatic metabolism; renal excretion of metabolites accounts for approximately 90% of elimination, with 10% fecal.
Renal excretion of unchanged drug and metabolites; 70% recovered in urine as parent and metabolites, 30% in feces.
Category C
Category C
Antimigraine Agent
Antimigraine Agent